Angiotensin-converting enzyme inhibitors and stroke risk: Benefit beyond blood pressure reduction?

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 1064-1076

  Hilleman, Daniel E ^a   Lucas Jr , B Daniel ^b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b CHARLESTON AREA MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors; Angiotensin converting enzyme inhibitors; Blood pressure; Hypertension; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SIMVASTATIN; STATINE DERIVATIVE;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 3543054543     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.1064.36137     Document Type: Review

References (66)

1. World Health Organization. The world health report 2000. Geneva, Switzerland: World Health Organization, 2000.
2. Murray CJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996.
3. Sarti C, Rastenyte D, Capaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke 2000;31:1588-601.
4. American Heart Association. Heart disease and stroke statistics: 2003 update. Available from http://www. americanheart.org/statistics/index.html. Accessed January 23, 2003.
5. Strauss SE, Majumdar SR, McAlister FA. New evidence for stroke prevention. JAMA 2002;288:1388-95.
6. Chalmers J, Chapman N. Challenges for the prevention of primary and secondary stroke: the importance of lowering blood pressure and total cardiovascular risk. Blood Press 2001;10:344-51.
7. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA 1999;281:1112-20.
8. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke council of the American Heart Association. Circulation 2001;103:163-82.
9. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. Arch Intern Med 1993;153:598-615.
10. Gorelick PB. Stroke prevention. Arch Neurol 1995;52:347-55.
11. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355:865-72.
12. Loun EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-69.
13. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens 1994;12(suppl 10):S5-14.
14. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-64.
15. MacMahon S, Sharpe N, Gamble G, et al. Randomised, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease. J Am Coll Cardiol 2000;36:438-43.
16. Pitt B, O'Neil B, Feldman R, et al, for the QUIET Study Group. The quinapril ischemic event trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63.
17. Teo K, Burton J, Buller C, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000;102:1748-54.
18. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
19. Cashin-Hemphilil L, Holmvang G, Chan R, Pitt B, Dinsmore R, Lees R. Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am J Cardiol 1999;83:43-7.
20. Bosch J, Yusuf S, Pogue J, et al, on behalf of the HOPE Investigators. Use of ramipril in preventing stroke: double blind randomized trial. BMJ 2002;324:1-5.
21. Food and Drug Administration. Approval for a new indication for ramipril: FDA, October 4, 2000. Available from http://www. fda.gov/medwatch/safety/2000/ Oct00.htm#altace. Accessed June 4, 2003.
22. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, for the Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001;358:2130-1.
23. Schrader J, Luders S. Preventing stroke: high risk patients should receive perindopril irrespective of blood pressure. BMJ 2002;324:687-8.
24. Staessen JA, Wang J, Lutgarde T. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;358:1305-15.
25. Svensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:E28-32.
26. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
27. The Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
28. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese cardiac study (CCS-1). Lancet 1995;345:686-7.
29. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
30. Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
31. Pfeffer MA, Braunwald E, Moye LA, et al, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction alter myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77.
32. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
33. Kober L, Torp-Pedersen C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
34. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative north Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
35. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
36. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
37. Estacio R, Jeffers B, Hiatt W, Biggerstaff S, Gifford N, Schrier R. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
38. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
39. United Kingdom Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
40. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish trial in old patients with hypertension-2 study. Lancet 1999;354:1751-6.
41. Hansson L, Lindholm L, Niskanen L, et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP) randomised trial. Lancet 1999;353:611-16.
42. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97.
43. Wing LMH, Reid CM, Ryan P, et al, for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin- converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
44. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
45. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
46. Dahlof B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
47. Messerli FH, Hanley DF, Gorelick PB. Blood pressure control in stroke patients: what should the consulting neurologist advise? Neurology 2002;59:23-5.
48. Yatsu FM, Zivin J. Hypertension in acute ischemic strokes: not to treat. Arch Neurol 1985;42:999-1000.
49. Wahlgren NG, McMahon DG, DeKeyser J, et al. Intravenous nimodipine west European stroke trial (IN-WEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994;4:204-10.
50. Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C. Blood pressure and risk of stroke in patients with cerebrovascular disease: the United Kingdom transient ischaemic attack collaborative group [letter]. BMJ 1996; 313:147.
51. Rodgers A, Neal B, MacMahon S. The effects of blood pressure lowering in cerebrovascular disease. Neurol Rev Int 1997;2:12-15.
52. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke 1997;28:2557-62.
53. PATS Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J 1995;108:710-17.
54. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20.
55. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998;18:588-99.
56. Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
57. Dyker AG, Grosset DG, Lees KR. Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997;28:580-3.
58. Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24 h after dosing: perindopril multicentre dose-response study group. Can J Cardiol 1996;12:1191-6.
59. Morgan T, Anderson A. Clinical efficacy of perindopril in hypertension. Clin Exp Pharmacol Physiol 1992;19(suppl): 61-5.
60. MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J 1991;66:206-11.
61. Squire IB, MacFadyen RJ, Reid JL, Devlin A, Lees KR. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. J Cardiovasc Pharmacol 1996;27:657-66.
62. MacMahon S, Rodgers A, Neal B, Woodward M, Chalmers J, on behalf of the PROGRESS Collaborative Group. Correspondence. Lancet 2001;358:1994-5.
63. Furberg CD, Pitt B. Are all angiotensin-converting enzyme inhibitors interchangeable? J Am Coll Cardiol 2001;37: 1456-60.
64. Alderman MH, Furberg CD, Kostis JB, et al. Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens 2002;15:917-23.
65. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and of vitamin E on atherosclerosis: results of randomized study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103:919-25.
66. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003;289:2560-72.